Estrogen Receptor Antagonists
"Estrogen Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that bind to and block or inhibit the activation of ESTROGEN RECEPTORS.
| Descriptor ID |
D065171
|
| MeSH Number(s) |
D06.347.295.500 D27.505.696.399.450.327.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Receptor Antagonists".
This graph shows the total number of publications written about "Estrogen Receptor Antagonists" by people in this website by year, and whether "Estrogen Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogen Receptor Antagonists" by people in Profiles.
-
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discov. 2020 02; 10(2):198-213.
-
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-a degrader activity in antitumor efficacy. Breast Cancer Res Treat. 2020 Jan; 179(1):67-77.
-
A meta-analysis of clinical benefit rates for fulvestrant 500?mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer. 2019 Nov; 26(6):703-711.
-
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2019 02 01; 5(2):e184475.
-
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Jun; 17(6):811-821.
-
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Clin Obstet Gynecol. 2016 03; 59(1):30-52.
-
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J Clin Oncol. 2015 Nov 10; 33(32):3781-7.
-
AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.